2020
Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis
Anantha-Narayanan M, Love K, Nagpal S, Sheikh AB, Regan CJ, Mena-Hurtado C. Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis. Expert Review Of Medical Devices 2020, 17: 533-539. PMID: 32525406, DOI: 10.1080/17434440.2020.1770593.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCoronary RestenosisFemoral ArteryHumansPaclitaxelPopliteal ArteryRandomized Controlled Trials as TopicStentsConceptsDrug-coated balloonsPlain old balloon angioplastyPeripheral arterial diseaseFP-ISRFP diseaseStent restenosisEfficacy of DCBUse of DCBPaclitaxel drug-coated balloonFirst-line therapyRecurrence of symptomsSelf-expanding nitinol stentsHigher patency rateLong-term safetyLesion revascularizationEndovascular therapyISR rateRandomized studyArterial diseaseBalloon angioplastyFemoropopliteal segmentPatency ratesCommon siteTerm safetyNitinol stents
2019
Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials
Anantha‐Narayanan M, Shah SM, Jelani Q, Garcia S, Ionescu C, Regan C, Mena‐Hurtado C. Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials. Catheterization And Cardiovascular Interventions 2019, 94: 139-148. PMID: 30838719, DOI: 10.1002/ccd.28176.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmputation, SurgicalAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleEquipment DesignFemaleFemoral ArteryHumansLimb SalvageMalePeripheral Arterial DiseasePopliteal ArteryRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeVascular Access DevicesVascular PatencyConceptsTarget vessel revascularizationPeripheral arterial diseaseFemoropopliteal diseaseBalloon angioplastyRate of TVRDrug-coated balloon angioplastyPlain old balloon angioplastyAvailable RCT dataDevice-related mortalityImproved vessel patencyPrimary safety endpointMainstay of therapyCochrane's Q statisticLate lumen lossDrug-coated balloonsRandom-effects modelQ statisticMajor amputationSafety endpointVessel revascularizationDCB groupPopliteal arteryArterial diseaseUse of DCBLumen loss